Literature DB >> 10534767

Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways.

J J Yeh1, D J Marsh, J Zedenius, T Dwight, L Delbridge, B G Robinson, C Eng.   

Abstract

Previous studies have demonstrated frequent loss of heterozygosity (LOH) of markers on chromosome arm 10q in both follicular thyroid carcinomas (FTCs) and follicular thyroid adenomas (FAs). A novel tumor suppressor gene, PTEN, has been mapped to 10q23.3 and is the susceptibility gene for Cowden syndrome, an autosomal dominant disorder characterized by multiple hamartomas and a risk of benign and malignant tumors of the breast and thyroid. Studies examining the relationship of somatic PTEN status and follicular thyroid neoplasms have only demonstrated a variable subset of tumors that have somatic monoallelic deletions of PTEN, suggesting that other tumor suppressor genes may be present in this region. We therefore sought to conduct a detailed examination of LOH of 20 polymorphic markers in a 19-cM region spanning 10q22-24, including PTEN, in 44 FAs and 17 FTCs. Using this fine-structure somatic mapping approach, we defined at least two novel regions of LOH in follicular adenomas and follicular carcinomas, suggesting the presence of at least two distinct tumor suppressor genes that may play a role in thyroid neoplasia. Furthermore, the difference in patterns of LOH in adenomas versus carcinomas lends additional support to the hypothesis that adenomas and carcinomas can develop along two separate, nonserial pathways. Genes Chromosomes Cancer 26:322-328, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534767     DOI: 10.1002/(sici)1098-2264(199912)26:4<322::aid-gcc6>3.0.co;2-#

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells.

Authors:  A Perren; P Komminoth; P Saremaslani; C Matter; S Feurer; J A Lees; P U Heitz; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Familial nonmedullary thyroid neoplasia.

Authors:  H Rubén Harach
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q.

Authors:  P S Moore; G Zamboni; A Brighenti; D Lissandrini; D Antonello; P Capelli; G Rigaud; M Falconi; A Scarpa
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

4.  Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway.

Authors:  Shawn D Larson; Lindsey N Jackson; Taylor S Riall; Tatsuo Uchida; Robert P Thomas; Suimin Qiu; B Mark Evers
Journal:  J Am Coll Surg       Date:  2007-02-23       Impact factor: 6.113

5.  New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer.

Authors:  Andrzej J Lachinski; Tomasz Stefaniak; Jarek Kobiela; Saxon Connor; Zbigniew Gruca; Zbigniew Sledzinski
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

6.  Genetic and biological subgroups of low-stage follicular thyroid cancer.

Authors:  Christopher A French; Erik K Alexander; Edmund S Cibas; Vania Nose; Julia Laguette; William Faquin; Jeff Garber; Francis Moore; Jonathan A Fletcher; P Reed Larsen; Todd G Kroll
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

7.  Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors.

Authors:  O Gimm; A Perren; L P Weng; D J Marsh; J J Yeh; U Ziebold; E Gil; R Hinze; L Delbridge; J A Lees; G L Mutter; B G Robinson; P Komminoth; H Dralle; C Eng
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

8.  Evaluation of Endocrine Neoplasms Using Fine Needle Aspiration Biopsy.

Authors:  Mary E. Barcus; Celeste N. Powers
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

9.  PTEN-knockdown disrupts the morphology, growth pattern and function of Nthy-Ori 3-1 cells by downregulating PAX8 expression.

Authors:  Zhuo Sun; Jinqi Lu; Muyu Wu; Changli Ouyang; Yueping Xing; Xiancun Hou; Zhenduo Shi; Yongping Wu
Journal:  Oncol Lett       Date:  2019-10-31       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.